Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
The DOI matches its Crossref record; 128 of the 132 references it cites were found in a registry or an index, and 4 are not checked yet.
Abstract
Vancomycin is a glycopeptide antibiotic that has been in clinical use for nearly 50 years as a penicillin alternative to treat penicillinase-producing strains of Staphylococcus aureus. It is one of the most widely used antibiotics in the United States for the treatment of serious gram-positive infections involving methicillin-resistant S. aureus (MRSA).1 Early use of vancomycin was associated with a number of adverse effects, including infusion-related toxicities, nephrotoxicity, and possible ototoxicity. Upon further investigation, it appears that the impurities in early formulations of vancomycin caused many of these adverse events.1–4 Its overall use was curtailed significantly with the development of semisynthetic penicillins (e.g., methicillin, oxacillin, nafcillin) that were considered less toxic.1–4 However, the steady rise in the number of MRSA infections since the early 1980s has once again brought vancomycin into the forefront as the primary treatment for infections caused by this organism....
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Self-citationHundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Autoinduction and signal transduction in the regulation of staphylococcal virulence
Novick, R. P. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03526.x · Cited by 1,280 · cited 1×
“aureus that is responsible for orchestrating the expression of adherence factors, biofilm production, tolerance to vancomycin, and virulence factors.(66) The agr locus has been a subject of intense study because there appears to be a relationship between polymorphism in this gene cluster and patient response to vancom…”
BackgroundMartindale. The Extra Pharmacopoeia.
(1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-5-687_2 · Cited by 1,111
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860 · cited 4×
“Hidayat et al.(53) prospectively investigated the efficacy and toxicity of adjusting vancomycin troughs to achieve an unbound concentration of at least four times the MIC.”
BackgroundInfluentialLevine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Self-citationSakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836 · cited 2×
“Sakoulas et al.(52) reported a significant correlation between vancomycin susceptibilities and patient outcome.”
BackgroundSelf-citation
Research works printed but not linked: 5
- Virgincar, 2004, Glycopeptides (dalabavancin, oritavancin, teicoplanin, vancomycin), 181
- Cooper, 1986, The development of vancomycin, 1
- Geraci, 1977, Vancomycin, Mayo Clin Proc, 52, 631
- Boffi El Amari, 2004, High versus standard dose vancomycin for osteomyelitis, Scand J Infect Dis., 36, 712
- Dangerfield, 1960, Clinical use of vancomycin, Antimicrob Agents Chemother, 61, 428
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
“What are the recommendations for vancomycin dosing and monitoring? These recommendations are based on a consensus statement of the American Society of Health-System Pharmacists, the IDSA, and the Society of Infectious Diseases Pharmacists on guidelines for vancomycin dosing [3,4].”
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Osmon, D. R., Berbari, E. F., Berendt, A. R., Lew, D., Zimmerli, W., Steckelberg, J. M., Rao, N., Hanssen, A., & Wilson, W. R. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis803 · Cited by 2,266
“R ec en t gu id el in es [7 , 8] fo r th e tr ea tm en t of m et hi ci lli nre si st an t St ap hy lo co cc us au re us (M R S A ) in fe ct io ns ha ve be en pu bl is he d.”
BackgroundLiu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir034 · Cited by 1,599
“What are the recommendations for vancomycin dosing and monitoring? These recommendations are based on a consensus statement of the American Society of Health-System Pharmacists, the IDSA, and The Society of Infectious Diseases Pharmacists on guidelines for vancomycin dosing [3, 4].”
BackgroundSelf-citationRybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., et al. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa036 · Cited by 1,202
“loading doses for severe infections in patients who were seriously ill.(1)”
BackgroundMethodResultInfluentialSelf-citationTunkel, A. R., Hasbun, R., Bhimraj, A., Byers, K., Kaplan, S. L., Scheld, W. M., van de Beek, D., Bleck, T. P., Garton, H. J. L., & Zunt, J. R. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw861 · Cited by 1,067
Osmon, D. R., Berbari, E. F., Berendt, A. R., Lew, D., Zimmerli, W., Steckelberg, J. M., Rao, N., Hanssen, A., & Wilson, W. R. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis966 · Cited by 924
General Principles of Antimicrobial Therapy
Leekha, S., Terrell, C. L., & Edson, R. S. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0639 · Cited by 878
Rybak, M. J., Lomaestro, B. M., Rotscahfer, J. C., Moellering, R. C., Craig, W. A., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · Clinical Infectious Diseases · doi:10.1086/600877 · Cited by 815
“comycin.[1] A computerized literature search of PubMed for”
BackgroundSelf-citationSpondylodiscitis: update on diagnosis and management
Gouliouris, T., Aliyu, S. H., & Brown, N. M. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq303 · Cited by 780
van Hal, S. J., Paterson, D. L., & Lodise, T. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01568-12 · Cited by 639
Hassoun, A., Linden, P. K., & Friedman, B. (2017) · Critical Care · doi:10.1186/s13054-017-1801-3 · Cited by 604
“While US guidelines recommend a fixed dose, European guidelines advise dosing vancomycin based on the trough plasma concentration (Cmin) [62] with the goal to achieve a vancomycin area under the curve to minimum inhibitory concentration (MIC) ratio ≥400 for as long as possible throughout the 24-h dosing interval [10].”
BackgroundThe Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Mazuski, J. E., Tessier, J. M., May, A. K., Sawyer, R. G., Nadler, E. P., Rosengart, M. R., Chang, P. K., O'Neill, P. J., Mollen, K. P., Huston, J. M., et al. (2017) · Surgical Infections · doi:10.1089/sur.2016.261 · Cited by 573
“Consider use of linezolid or daptomycin for empiric or pathogen-directed therapy of infections from vancomycin-resistant Enterococcus spp. (VRE) and as an alternative to vancomycin for infections from MRSA in adults and children (Grade 2-”
InfluentialLodise, T. P., Patel, N., Lomaestro, B. M., Rodvold, K. A., & Drusano, G. L. (2009) · Clinical Infectious Diseases · doi:10.1086/600884 · Cited by 554
“5 mg/dL or 50%, whichever was greater, on at least 2 consecutive days during the period from initiation of vancomycin therapy to 72 h after completion of therapy [1–4, 13].”
Self-citationDoron, S., & Davidson, L. E. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0358 · Cited by 415
Clinical Management of Staphylococcus aureus Bacteremia: A Review
Holland, T. L., Arnold, C., & Fowler, V. G. (2014) · JAMA · doi:10.1001/jama.2014.9743 · Cited by 449
(2020) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000003668 · Cited by 423
Elyasi, S., Khalili, H., Dashti-Khavidaki, S., & Mohammadpour, A. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1259-9 · Cited by 436
“The Infectious Diseases Society of America (IDSA) recently recommended higher doses of vancomycin to achieve trough concentrations of 10–20 μg/mL [62–64].”
BackgroundThe Nephrotoxicity of Vancomycin
Filippone, E., Kraft, W., & Farber, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.726 · Cited by 416
Rybak, M. J., Lomaestro, B. M., Rotschafer, J. C., Moellering, R. C., Craig, W. A., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.11.1275 · Cited by 403
Self-citationAre Vancomycin Trough Concentrations Adequate for Optimal Dosing?
Neely, M. N., Youn, G., Jones, B., Jelliffe, R. W., Drusano, G. L., Rodvold, K. A., & Lodise, T. P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01653-13 · Cited by 392
“pneumonia and 10 to 20 mg/liter for all others (1).”
BackgroundMethodResultInfluentialNeely, M. N., Kato, L., Youn, G., Kraler, L., Bayard, D., van Guilder, M., Schumitzky, A., Yamada, W., Jones, B., & Minejima, E. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02042-17 · Cited by 359
Prevention and Treatment of Cancer-Related Infections
Baden, L. R., Bensinger, W., Angarone, M., Casper, C., Dubberke, E. R., Freifeld, A. G., Garzon, R., Greene, J. N., Greer, J. P., Ito, J. I., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0146 · Cited by 368
New Lipoglycopeptides: A Comparative Review of Dalbavancin, Oritavancin and Telavancin
Zhanel, G. G., Calic, D., Schweizer, F., Zelenitsky, S., Adam, H., Lagacé-Wiens, P. R. S., Rubinstein, E., Gin, A. S., Hoban, D. J., & Karlowsky, J. A. (2010) · Drugs · doi:10.2165/11534440-000000000-00000 · Cited by 352
Therapeutic drug monitoring of antimicrobials
Roberts, J. A., Norris, R., Paterson, D. L., & Martin, J. H. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04080.x · Cited by 316
Innovative approaches to optimizing the delivery of vancomycin in individual patients
Pai, M. P., Neely, M., Rodvold, K. A., & Lodise, T. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.016 · Cited by 292
Svetitsky, S., Leibovici, L., & Paul, M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00341-09 · Cited by 275
“As these doses are associated with increased nephrotoxicity (36), monitoring of trough serum levels is recommended (56).”
BackgroundDevelopments in Glycopeptide Antibiotics
Blaskovich, M. A. T., Hansford, K. A., Butler, M. S., Jia, Z., Mark, A. E., & Cooper, M. A. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00258 · Cited by 265
Lin, S., Cheng, X., Zhu, J., Wang, B., Jelinek, D., Zhao, Y., Wu, T.-Y., Horrillo, A., Tan, J., Yeung, J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq4539 · Cited by 255
“S14 and S15, both Rmax and AUCISF increased with the increase of drug dosages for all three animals.”
BackgroundInfluentialImproved Vancomycin Dosing in Children Using Area Under the Curve Exposure
Le, J., Bradley, J. S., Murray, W., Romanowski, G. L., Tran, T. T., Nguyen, N., Cho, S., Natale, S., Bui, I., Tran, T. M., et al. (2013) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318286378e · Cited by 262
“The importance of proper dosing of vancomycin is illustrated in a consensus national guideline endorsed by prominent professional societies.(4) Recommendations derived from this guideline were supported by data from adults.”
MethodOptimizing the Clinical Use of Vancomycin
Álvarez, R., López Cortés, L. E., Molina, J., Cisneros, J. M., & Pachón, J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03147-14 · Cited by 258
“The main guidelines recommendations are to administer dosages of 15 to 20 mg/kg of body weight every 8 to 12 h to achieve target trough levels of 15 to 20 mg/liter and to start monitoring the vancomycin trough concentration before the fourth dose (4).”
BackgroundInfluentialMcGill, F., Heyderman, R. S., Michael, B. D., Defres, S., Beeching, N. J., Borrow, R., Glennie, L., Gaillemin, O., Wyncoll, D., Kaczmarski, E., et al. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.01.007 · Cited by 254
Bosso, J. A., Nappi, J., Rudisill, C., Wellein, M., Bookstaver, P. B., Swindler, J., & Mauldin, P. D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00168-11 · Cited by 252
“Another relevant study, using Monte Carlo simulations and considering various dosing regimens and staphylococcal MICs determined that the necessary doses to achieve a target therapeutic area under the curve (AUC)/MIC ratio of 400 for organisms with an MIC of 2 mg/liter would be associated with a 35% incidence of nephr…”
BackgroundInfluentialHamada, Y., Tokimatsu, I., Mikamo, H., Kimura, M., Seki, M., Takakura, S., Ohmagari, N., Takahashi, Y., Kasahara, K., Matsumoto, K., et al. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-013-0607-8 · Cited by 248
“Compared with other antimicrobial agents, the therapeutic range is narrow in VCM, and therapeutic drug monitoring (TDM) is required for maximizing efficacy while minimizing the onset of these toxicities [12–14].”
BackgroundMethodInfluentialRodvold, K. A., George, J. M., & Yoo, L. (2011) · Clinical Pharmacokinetics · doi:10.2165/11594090-000000000-00000 · Cited by 246
“A great deal of attention has recently been paid to appropriate dosing of vancomycin, particularly in lower respiratory tract infections.([125,126]) However, only a limited number of studies have evaluated ELF concentrations of vancomycin and assessed its plasma and intrapulmonary disposition (table XI).”
Vancomycin: We Can't Get There From Here
Patel, N., Pai, M. P., Rodvold, K. A., Lomaestro, B., Drusano, G. L., & Lodise, T. P. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir078 · Cited by 247
Self-citationMethicillin-resistant Staphylococcus aureus: the superbug
Ippolito, G., Leone, S., Lauria, F. N., Nicastri, E., & Wenzel, R. P. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2010.05.003 · Cited by 244
Review of vancomycin-induced renal toxicity: an update
Bamgbola, O. (2016) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018816638223 · Cited by 239
Luther, M. K., Timbrook, T. T., Caffrey, A. R., Dosa, D., Lodise, T. P., & LaPlante, K. L. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000002769 · Cited by 235
Introduction to Drug Pharmacokinetics in the Critically III Patient
Smith, B. S., Yogaratnam, D., Levasseur-Franklin, K. E., Forni, A., & Fong, J. (2012) · Chest · doi:10.1378/chest.11-1396 · Cited by 230
Macrocyclic Drugs and Synthetic Methodologies toward Macrocycles
Yu, X., & Sun, D. (2013) · Molecules · doi:10.3390/molecules18066230 · Cited by 231
“Among them, vancomycin is a macrocyclic glycopeptide antibiotics for the treatment of Gram-positive bacterial infections, such as methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumonia [9,10].”
BackgroundRoberts, J. A., Taccone, F. S., Udy, A. A., Vincent, J.-L., Jacobs, F., & Lipman, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01708-10 · Cited by 226
“The aim of this regimen was to provide serum drug concentrations between 20 and 30 mg/liter (28).”
BackgroundMethodVancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia
Holmes, N. E., Turnidge, J. D., Munckhof, W. J., Robinson, J. O., Korman, T. M., O'Sullivan, M. V. N., Anderson, T. L., Roberts, S. A., Warren, S. J. C., Gao, W., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01485-12 · Cited by 224
“Recently, consensus guidelines were published in the United States to assist clinicians and pharmacists regarding vancomycin dosing strategies (14).”
BackgroundInfluentialMoore, C. L., Osaki-Kiyan, P., Haque, N. Z., Perri, M. B., Donabedian, S., & Zervos, M. J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir764 · Cited by 220
Standiford, H. C., Chan, S., Tripoli, M., Weekes, E., & Forrest, G. N. (2012) · Infection Control & Hospital Epidemiology · doi:10.1086/664909 · Cited by 215
“The guidelines for monitoring vancomycin, which called for an increase in its dosing, were published in January 2009, 6 months after our program was discontinued.(10) Also, there was an increase in the number of clinical culture isolates of vancomycin-resistant Enterococcus (but not bloodstream infections) in FY 2009…”
BackgroundWong, G., Brinkman, A., Benefield, R. J., Carlier, M., De Waele, J. J., El Helali, N., Frey, O., Harbarth, S., Huttner, A., McWhinney, B., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt523 · Cited by 215
Clinical Pharmacology of Antibiotics
Eyler, R. F., & Shvets, K. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08140718 · Cited by 212
“On the basis of data from animal, in vitro, and human studies, research suggests that the AUC:MIC ratio is the pharmacodynamic parameter linked to vancomycin effectiveness (24).”
BackgroundInfluentialCataldo, M. A., Tacconelli, E., Grilli, E., Pea, F., & Petrosillo, N. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr442 · Cited by 204
Mo, X., Zhang, D., Liu, K., Zhao, X., Li, X., & Wang, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021291 · Cited by 188
The Whole Price of Vancomycin: Toxicities, Troughs, and Time
Jeffres, M. N. (2017) · Drugs · doi:10.1007/s40265-017-0764-7 · Cited by 191
Matsumoto, K., Takesue, Y., Ohmagari, N., Mochizuki, T., Mikamo, H., Seki, M., Takakura, S., Tokimatsu, I., Takahashi, Y., Kasahara, K., et al. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-013-0599-4 · Cited by 184
Incidence and Risk Factors Influencing the Development of Vancomycin Nephrotoxicity in Children
McKamy, S., Hernandez, E., Jahng, M., Moriwaki, T., Deveikis, A., & Le, J. (2011) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2010.08.019 · Cited by 186
Benefits of Therapeutic Drug Monitoring of Vancomycin: A Systematic Review and Meta-Analysis
Ye, Z.-K., Tang, H.-L., & Zhai, S.-D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077169 · Cited by 181
“The consensus review from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists, as well as the consensus review from the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring all recommended…”
BackgroundThabit, A. K., Crandon, J. L., & Nicolau, D. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.993381 · Cited by 160
“[143], as well as several in vitro and in vivo studies a target vancomycin AUC/MIC value of at least 400 has been established for maximized efficacy, minimized toxicity, and prevention of resistance development [34].”
BackgroundMethodInfluentialJavanbakht, S., Pooresmaeil, M., Hashemi, H., & Namazi, H. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.07.181 · Cited by 180
Gomes, D. M., Smotherman, C., Birch, A., Dupree, L., Della Vecchia, B. J., Kraemer, D. F., & Jankowski, C. A. (2014) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1428 · Cited by 180
He, N., Su, S., Ye, Z., Du, G., He, B., Li, D., Liu, Y., Yang, K., Zhang, X., Zhang, Y., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1536 · Cited by 155
Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy
Wong-Beringer, A., Joo, J., Tse, E., & Beringer, P. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.10.013 · Cited by 178
“Excellent reviews on vancomycin nephrotoxicity with traditionaldosinghavebeenpublishedpreviously [2,3].”
BackgroundPharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing
Onufrak, N. J., Forrest, A., & Gonzalez, D. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.06.015 · Cited by 170
Lodise, T. P., Drusano, G. L., Zasowski, E., Dihmess, A., Lazariu, V., Cosler, L., & McNutt, L.-A. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu398 · Cited by 167
“Although expert guidelines recommend trough monitoring [1, 2], this was not an unexpected finding from an exposure–response perspective.”
BackgroundMethodInfluentialOritavancin: Mechanism of Action
Zhanel, G. G., Schweizer, F., & Karlowsky, J. A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir920 · Cited by 167
“MRSA, vancomycin is plagued by poor penetration into certain tissues (eg, lung) and slow bactericidal activity [4, 6].”
BackgroundThe 6R’s of drug induced nephrotoxicity
Awdishu, L., & Mehta, R. L. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0536-3 · Cited by 161
“National guidelines on the use of vancomycin have recommended higher target trough concentrations to obtain a high area under the curve (AUC) to minimum inhibitory concentration (MIC) ratio [33, 34].”
BackgroundCano, E. L., Haque, N. Z., Welch, V. L., Cely, C. M., Peyrani, P., Scerpella, E. G., Ford, K. D., Zervos, M. J., Ramirez, J. A., & Kett, D. H. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.12.013 · Cited by 161
Increasing Vancomycin Serum Trough Concentrations and Incidence of Nephrotoxicity
Pritchard, L., Baker, C., Leggett, J., Sehdev, P., Brown, A., & Bayley, K. B. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.07.025 · Cited by 161
Ex Vivo Perfusion Treatment of Infection in Human Donor Lungs
Nakajima, D., Cypel, M., Bonato, R., Machuca, T., İskender, İ., Hashimoto, K., S, V. L., Chen, M., Coutinho, R., Azad, S., et al. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13562 · Cited by 157
“Vancomycin is also bactericidal in a time-dependent fashion, and the ratio of the 24-h area under the curve (AUC) to the MIC should be 400h for clinical effectiveness (21).”
BackgroundAntonoplis, A., Zang, X., Huttner, M. A., Chong, K. K. L., Lee, Y. B., Co, J. Y., Amieva, M. R., Kline, K. A., Wender, P. A., & Cegelski, L. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b08711 · Cited by 167
Matsumoto, K., Oda, K., Shoji, K., Hanai, Y., Takahashi, Y., Fujii, S., Hamada, Y., Kimura, T., Mayumi, T., Ueda, T., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030489 · Cited by 176
“Conversely, the updated Chinese guideline recommended troughguided dosing and AUC-guided dosing at the same strength, considering institutions in which Bayesian software is not available and the possibility of poor feasibility of measuring twopoint samples in a first-order pharmacokinetic (PK) equation [13].”
BackgroundMethodInfluentialCUESTA, N. R., Martín‐Suárez, A., Pérez, M. P., Martín-González, F., & Gatta, M. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03679.x · Cited by 161
Thomson, A. H., Staatz, C. E., Tobin, C. M., Gall, M., & Lovering, A. M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp085 · Cited by 151
“aureus lower respiratory tract infections and this target ratio has recently been recommended in an American consensus review.(42) In the present study, 87% of patients were predicted to achieve satisfactory AUC24/MIC ratios if the new guidelines were followed.”
BackgroundZhanel, G. G., Sniezek, G., Schweizer, F., Zelenitsky, S. A., Lagacé-Wiens, P. R. S., Rubinstein, E., Gin, A. S., Hoban, D. J., & Karlowsky, J. A. (2009) · Drugs · doi:10.2165/00003495-200969070-00003 · Cited by 168
Appropriate antimicrobial therapy in the era of multidrug-resistant human pathogens
Pogue, J. M., Kaye, K. S., Cohen, D. A., & Marchaim, D. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.12.025 · Cited by 156
Zasowski, E. J., Murray, K. P., Trinh, T. D., Finch, N. A., Pogue, J. M., Mynatt, R. P., & Rybak, M. J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01684-17 · Cited by 149
Self-citationHobbs, A. L. V., Shea, K. M., Roberts, K. M., & Daley, M. J. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1653 · Cited by 155
“Although literature suggests that trough concentrations may not always correlate with the AUC/MIC ratio, it is often the most commonly used method for assessing therapeutic concentrations, and a concentration of 15–20 lg/mL is most frequently recommended, although a target as low as 10 lg/ mL is accepted for some indi…”
BackgroundBroeker, A., Nardecchia, M., Klinker, K. P., Derendorf, H., Day, R. O., Marriott, D. J. E., Carland, J. E., STOCKER, S. L., & Wicha, S. G. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.02.029 · Cited by 144
Vancomycin-Associated Nephrotoxicity: Grave Concern or Death by Character Assassination?
Hazlewood, K. A., Brouse, S. D., Pitcher, W. D., & Hall, R. G. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.05.031 · Cited by 154
Antibiotic dosing in critical illness
McKenzie, C. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq516 · Cited by 144
Turner, R. B., Kojiro, K., Shephard, E. A., Won, R., Chang, E., Chan, D., & Elbarbry, F. (2018) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2191 · Cited by 135
“Current treatment guidelines recommend monitoring trough levels to minimize toxicity and maximize efficacy.(2) Data suggest that the vancomycin pharmacodynamic parameter most closely linked to efficacy is the ratio of the daily area under the curve (AUC) to minimum inhibitory concentration (MIC).”
BackgroundHa, M. A., & Sieg, A. C. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1882 · Cited by 141
“Vancomycin is a glycopeptide antibiotic whose efficacy is associated with maintaining an AUC: MIC ratio of ≥ 400.(49) Few studies have examined the PK of vancomycin in patients receiving ECMO.”
BackgroundMoise, P. A., North, D. S., Steenbergen, J. N., & Sakoulas, G. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70200-2 · Cited by 130
Antimicrobial Stewardship in the NICU
Cantey, J. B., & Patel, S. J. (2014) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2014.01.005 · Cited by 126
Ye, Z., Chen, Y., Chen, K., Zhang, X., Du, G., He, B., Li, D., Liu, Y.-N., Yang, K., Zhang, Y., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw254 · Cited by 125
Native valve right sided infective endocarditis
Akinosoglou, K., Apostolakis, E. E., Marangos, M. N., & Pasvol, G. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.01.010 · Cited by 136
“The standard recommendation for trough concentrations of vancomycin of 5–10 mg/l is inadequate for serious infections such as endocarditis, since in high inoculum infections, such levels are likely to select for heterogeneous resistant strains [102].”
BackgroundJamal, J., Udy, A. A., Lipman, J., & Roberts, J. A. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000317 · Cited by 127
Nguyen, H. M., & Graber, C. J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp377 · Cited by 132
Jacob, J. T., & DiazGranados, C. A. (2012) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2012.08.005 · Cited by 121
“The vancomycin therapeutic monitoring guidelines from the American Society of Health-System Pharmacists, IDSA, and the Society for Infectious Disease Pharmacists recommend considering alternative therapies for MRSA infections if the MIC is 2 mg/l.(39) In contrast, the more recent IDSA guidelines for the treatment of M…”
Vertical-flow paper SERS system for therapeutic drug monitoring of flucytosine in serum
Berger, A. G., Restaino, S. M., & White, I. M. (2016) · Analytica Chimica Acta · doi:10.1016/j.aca.2016.10.035 · Cited by 122
Staphylococcus aureus Infections in Hemodialysis: What a Nephrologist Should Know
Vandecasteele, S. J., Boelaert, J. R., & Vriese, A. S. D. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01590309 · Cited by 141
“Vancomycin can be dosed intermittently on hemodialysis days, with trough levels being the most practical and accurate method to monitor effectiveness (98,99).”
BackgroundMethodInfluentialBelley, A. C., McKay, G. A., Arhin, F. F., Sarmiento, I., Beaulieu, S., Fadhil, I., Parr, T. R., & Moeck, G. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00760-10 · Cited by 120
“aureus (VISA) and heterogeneous VISA (hVISA), has also been described and poses a clinical challenge (1, 17).”
BackgroundZelenitsky, S. A., Rubinstein, E., Ariano, R. E., Iacovides, H., Dodek, P., Mirzanejad, Y., & Kumar, A. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.10.015 · Cited by 116
“In response to increasing concerns regarding the efficacy of vancomycin, consensus guidelines for more aggressive dosing and therapeutic drug monitoring were published in 2009 [4].”
BackgroundNephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime
Rutter, W. C., Cox, J. N., Martin, C. A., Burgess, D. R., & Burgess, D. S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02089-16 · Cited by 116
Khan, A. R., Khan, S., Zimmerman, V. A., Baddour, L. M., & Tleyjeh, I. M. (2010) · Clinical Infectious Diseases · doi:10.1086/656735 · Cited by 126
Vancomycin-Associated Nephrotoxicity in the Critically Ill
Hanrahan, T. P., Harlow, G., HUTCHINSON, J. H., Dulhunty, J. M., Lipman, J., Whitehouse, T., & Roberts, J. A. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000514 · Cited by 111
“Furthermore, 11% of patients (150/1,430) were identified as MRSA positive.”
BackgroundInfluentialMen, P., Li, H.-B., Zhai, S.-D., & Zhao, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146224 · Cited by 118
“In vitro tests and limited human trials have shown that the ratio of the 24-hour area under the concentration-time curve and MIC (AUC0-24/ MIC) of vancomycin is the pharmacokinetic/pharmacodynamics (PK/PD) parameter that is most relevant to its clinical effectiveness in the treatment of Staphylococcus aureus infection…”
BackgroundSuzuki, Y., Kawasaki, K., Sato, Y., Tokimatsu, I., Itoh, H., Hiramatsu, K., Takeyama, M., & Kadota, J. (2012) · Chemotherapy · doi:10.1159/000343162 · Cited by 124
Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie
Dalhoff, K., Abele‐Horn, M., Andreas, S., Bauer, T. T., von Baum, H., Deja, M., Ewig, S., Gastmeier, P., Gatermann, S. G., Gerlach, H., et al. (2012) · Pneumologie · doi:10.1055/s-0032-1325924 · Cited by 110
Chong, Y. P., Park, S., Kim, H. S., Kim, E. S., Kim, M., Park, K., Kim, S., Lee, S., Choi, S., Jeong, J., et al. (2013) · Medicine · doi:10.1097/md.0b013e318289ff1e · Cited by 113
“aureus bacteremia.(19,46) Patients were excluded if 1) they had polymicrobial bacteremia, 2) they died or were discharged before positive blood culture results, or 3) they had clinically insignificant SAB, which means that S.”
BackgroundKullar, R., Leonard, S. N., Davis, S. L., Delgado, G., Pogue, J. M., Wahby, K. A., Falcione, B. A., & Rybak, M. J. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.5.441 · Cited by 109
“Similar cost reduction may not be realized after implementation of the high-trough nomogram, as dosage adjustments are more commonly necessary to achieve the narrower target range, and considering new vancomycin dosing guidelines that recommend trough concentration monitoring.(23)”
BackgroundInfluentialSelf-citationRecent changes in vancomycin use in renal failure
Vandecasteele, S. J., & Vriese, A. S. D. (2010) · Kidney International · doi:10.1038/ki.2010.35 · Cited by 106
Metadata
- Authors
- Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Albany Medical Center Hospital (US)
- University of Minnesota (US)
- Beth Israel Deaconess Medical Center (US)
- University of Wisconsin–Madison (US)
- New Orleans, LA
- Ochsner Health System (US)
- Division of General Internal Medicine, WSU
- Corresponding author
- Rybak, Michael
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01-01
- Volume
- 66
- Issue
- 1
- Pages
- 82-98
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2133120422
- Semantic Scholar
- f97f86b0eb5acbf0d7b5f8d4197a9e67f28c94ab
- Cited by
- 1,795
- References
- 130
- Citations by year
- 2026: 41 · 2025: 63 · 2024: 60 · 2023: 72 · 2022: 94 · 2021: 110 · 2020: 135 · 2019: 129 · 2018: 123 · 2017: 113 · 2016: 104 · 2015: 120 · 2014: 122 · 2013: 119 · 2012: 120
- FWCI
- 61.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Health-System Pharmacy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin, therapeutic drug monitoring, glycopeptides, methicillin-resistant Staphylococcus aureus, MRSA infection, Gram-positive bacterial infections, nephrotoxicity, ototoxicity, infusion-related toxicity, adverse drug reactions, pharmacokinetics, pharmacodynamics
- MeSH terms
- Adult, Anti-Bacterial Agents, Humans, Vancomycin, Drug Monitoring, Gram-Positive Bacterial Infections, Practice Guidelines as Topic, Vancomycin Resistance, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.